US Patent

US11833245 — Vasoconstriction compositions and methods of use

Method of Use · Assigned to Eye Therapies LLC · Expires 2029-07-27 · 3y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions, preferably containing brimonidine, for inducing vasoconstriction at low concentrations.

USPTO Abstract

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Drugs covered by this patent

Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2222`	—	Alphagan

Patent Metadata

Patent number: US11833245
Jurisdiction: US
Classification: Method of Use
Expires: 2029-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Eye Therapies LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.